Pulse Radiotherapy to Overcome Metastatic Immune System Evasion in Lung Cancer

Sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Study ID
NCT06622174
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pulse radiotherapy — RADIATION
    Pulsed radiotherapy combined with PD(L)-1 inhibitors targeting 2 to 5 progressive extracranial lesions per cycle

Study Details

This phase I study aims to evaluate the safety and effectiveness of adaptive pulsed radiotherapy combined with immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC) resistant to immune checkpoint inhibitors. The primary goal is to assess treatment-related toxicity, while secondary objectives include progression-free survival, overall survival, and quality of life. The study will enroll 32 patients.

Key Dates

First listed
Oct 2, 2024
Start date
Aug 20, 2026
Status verified
Jul 2026
Primary completion
Jul 31, 2028
Completion
Aug 31, 2029

Study Design

Enrollment
32 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Pulse Radiotherapy
    Pulsed radiotherapy combined with PD(L)-1 inhibitors targeting 2 to 5 progressive extracranial lesions per cycle

Primary Outcome Measure

Toxicity [ Time Frame: Within 180 days of radiotherapy completion ]

Central Contacts

Find similar trials

Nationwide
Lung cancer trialsOncology trialsLung oncology trialsLung disease trials

Related Studies